Determinants of morbidities and mortality in acromegaly.
Leandro K J de PinhoPaula da Silva RochaElisa Baranski LambackMônica Roberto GadelhaPublished in: Archives of endocrinology and metabolism (2020)
Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease. Arch Endocrinol Metab. 2019;63(6):630-7.
Keyphrases
- risk factors
- cardiovascular disease
- cardiovascular events
- growth hormone
- end stage renal disease
- case control
- healthcare
- chronic kidney disease
- newly diagnosed
- physical activity
- randomized controlled trial
- bone mineral density
- peritoneal dialysis
- case report
- middle aged
- metabolic syndrome
- patient reported outcomes
- soft tissue
- replacement therapy
- patient reported
- bone loss
- respiratory tract
- smoking cessation
- drug induced